Rupert Bauersachs (Darmstadt, Germany) talks to Cardiovascular News about the VOYAGER-PAD trial, the results of which he presented at the American College of Cardiology’s 70th Annual Scientific Session (ACC.21, 15–17 May, virtual) and which highlighted a reduced risk of ischaemic events in peripheral artierial disease (PAD) patients receiving rivaroxaban. The analysis, presented by Bauersachs, focused […]
The post ACC 2021: VOYAGER-PAD analysis shows totality of ischaemic events reduced following rivaroxaban use appeared first on Vascular News.